Oxford Immunotec Global PLC Form 4

March 22, 2017

# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

**OMB APPROVAL** 

subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

if no longer

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person \* Keiley Elizabeth M

(Middle)

(Zip)

2. Issuer Name and Ticker or Trading Symbol

Oxford Immunotec Global PLC

[OXFD] 3. Date of Earliest Transaction

(Month/Day/Year)

03/20/2017

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

Senior VP & General Counsel

Director 10% Owner X\_ Officer (give title below)

Other (specify

C/O OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE

(First)

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Table I. Non Derivative Securities Acquired Disposed of or Panaficially Ov

#### ABINGDON. OXFORDSHIRE, X0 OX14 4RZ

(State)

(,)	(=)	Table	e I - Non-D	erivative	Secur	ities Acqu	uirea, Disposea oi	, or Beneficial	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)		3. Transactio Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Ordinary Shares	03/20/2017		M	3,000	A	\$ 0.81	25,429	D	
Ordinary Shares	03/20/2017		S <u>(1)</u>	3,000	D	\$ 16.05	22,429	D	
Ordinary Shares	03/20/2017		M	8,185	A	\$ 0.81	30,614	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: Oxford Immunotec Global PLC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

> 8. F Der Sec (Ins

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number out Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	\$ 0.81	03/20/2017		M	3,000	(2)	09/30/2022	Ordinary Shares	3,000
Share Option (Right to Buy)	\$ 0.81	03/20/2017		M	8,185	(2)	09/30/2022	Ordinary Shares	8,185

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Keiley Elizabeth M C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON, OXFORDSHIRE, X0 OX14 4RZ

Senior VP & General Counsel

### **Signatures**

/s/ Elizabeth M. Keiley

03/22/2017

\*\*Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reporting Owners 2

### Edgar Filing: Oxford Immunotec Global PLC - Form 4

- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8 2016.
- (2) Exercise from an option granted October 29, 2012, which became fully vested on September 30, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.